drugset / Trial / NCT01029704
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study was to assess the effect of EGT0001442 on fasting plasma glucose after 28 days of treatment in subjects with type 2 diabetes. The study also assessed the pharmacokinetics, safety and tolerability of EGT0001442, the effect on weight and HbA1c as well as the effect EGT0001442 has on the amount of glucose produced in the body by the urine.
Timeline
- Start
- 2009-12
- Primary completion
- 2010-07
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bexagliflozin | Small molecule | 5 mg | Oral |
| Subject | Bexagliflozin | Small molecule | 10 mg | Oral |
| Subject | Bexagliflozin | Small molecule | 20 mg | Oral |
| Subject | Bexagliflozin | Small molecule | 50 mg | Oral |